Rutas Eglites Gimenes Arsta Prakse SIA

At Rutas Eglites Gimenes Arsta Prakse SIA in Kuldiga, the cardiovascular research portfolio focuses on major heart and blood vessel conditions, including atherosclerotic cardiovascular disease and atrial fibrillation. The trials are centered on testing new approaches to lower the risk of heart attack, stroke, and other serious complications.

• Prevention of major adverse cardiovascular events in people with established or high-risk ASCVD
• Stroke and systemic embolism prevention in atrial fibrillation
• Evaluation of treatments aimed at reducing cardiovascular risk compared with standard care or placebo

These studies help assess whether newer therapies can improve protection against life-threatening cardiovascular outcomes and offer better long-term risk reduction for patients.

The site also participates in research on nutritional and metabolic diseases, with a strong emphasis on type 2 diabetes and severe hypertriglyceridemia. This work explores whether emerging treatments can improve blood sugar control and lower harmful fat levels in the bloodstream.

• Better glucose control in type 2 diabetes that is not adequately managed with current therapy
• Reduction of elevated triglycerides in severe hypertriglyceridemia
• Assessment of treatment effectiveness for metabolic risk factors linked to cardiovascular complications

Overall, the research aims to support more effective management of metabolic disorders that often overlap with heart disease risk, combining prevention and treatment goals in one clinical setting.